Compare NUVL & TX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | TX |
|---|---|---|
| Founded | 2017 | 1961 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.5B |
| IPO Year | 2021 | 2006 |
| Metric | NUVL | TX |
|---|---|---|
| Price | $99.24 | $39.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $135.33 | $36.92 |
| AVG Volume (30 Days) | ★ 443.1K | 254.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.73% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.25 |
| Revenue Next Year | $1,064.25 | $6.86 |
| P/E Ratio | ★ N/A | $20.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $55.54 | $24.00 |
| 52 Week High | $113.02 | $45.57 |
| Indicator | NUVL | TX |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 29.19 |
| Support Level | $98.65 | $37.08 |
| Resistance Level | $107.13 | $45.57 |
| Average True Range (ATR) | 4.05 | 1.29 |
| MACD | -0.31 | -0.58 |
| Stochastic Oscillator | 19.28 | 6.76 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Ternium SA is a flat steel producer operating in Mexico, Brazil, Argentina, Colombia, the southern United States, and Central America. It produces finished and semi-finished steel products and iron ore, which are sold either directly to steel manufacturers and steel processors or end-users. The company operates in two segments: Steel and Mining. In its Steel segment, the company produces slabs, billets & round bars, hot-rolled coils & sheets, bars & stirrups, wire rods, steel pipes, and other products. The Mining segment sells iron ore as concentrates (fines) and pellets. The vast majority of its revenue comes from the Steel segment and geographically from Mexico.